Last reviewed · How we verify
Reverse hybrid regimen
Reverse hybrid regimen combines antiretroviral therapy with other treatments to suppress HIV replication.
Reverse hybrid regimen combines antiretroviral therapy with other treatments to suppress HIV replication. Used for HIV-1 infection.
At a glance
| Generic name | Reverse hybrid regimen |
|---|---|
| Sponsor | Ayman Magd Eldin Mohammad Sadek |
| Drug class | Antiretroviral therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | FDA-approved |
Mechanism of action
This approach aims to reduce the viral load and prevent the development of drug resistance. By combining multiple therapies, the reverse hybrid regimen can provide a more effective treatment for HIV infection.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Kuwa Free! - Live Free! (NA)
- Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy (NA)
- Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy. (NA)
- Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt (PHASE4)
- Tailored Juice-guided Eradication Therapy (NA)
- Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reverse hybrid regimen CI brief — competitive landscape report
- Reverse hybrid regimen updates RSS · CI watch RSS
- Ayman Magd Eldin Mohammad Sadek portfolio CI